Communiqués Palisade Bio, Inc.

Actions

PALI

US6963894026

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 17:49:24 23/09/2026			Varia. 5j.	Varia. 1 janv.
1,605 ^USD	-5,03%		-3,85%	-30,85%

15:37	Palisade Bio obtient l’autorisation de lancer un essai de phase 2 sur un traitement de la rectocolite hémorragique au Canada	MT
22/09	Palisade Bio obtient le feu vert de la FDA pour PALI-2108 dans la maladie de Crohn	MT

Communiqués

14:45	Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance	AQ
22/09	Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD	AQ
21/09	Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum	AQ
03/09	Palisade Bio to Participate in Upcoming Investor Conferences	AQ
10/08	Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development	AQ
10/07	Palisade Bio to Participate in the Leerink Partners Therapeutics Forum	AQ
29/06	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis	AQ
11/06	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors	AQ
10/06	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium	AQ
09/06	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium	AQ
27/05	Palisade Bio to Participate in the Jefferies Global Healthcare Conference	AQ
12/05	Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108	AQ
05/05	Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis	AQ
17/04	Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week 2026	AQ
16/04	Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026	AQ
08/04	Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference	AQ
30/03	Palisade Bio : Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease	PU
30/03	Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease	AQ
02/03	Palisade Bio Announces Participation in Two Upcoming Investor Conferences	AQ
23/02	Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026	AQ
17/02	Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board	AQ
09/02	Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium	AQ
05/02	Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
29/01	Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board	AQ
19/01	Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences	AQ